- In September 2024, BD has been recognized in the top 10 for overall transparency and awarded Best Code of Conduct U.S. Transparency Awards. This accolade underscores BD's commitment to ethical practices, emphasizing clarity and accessibility in its corporate disclosures, which foster trust among stakeholders and reflect the company's core values in health care innovation
- In July 2024, Siemens Healthineers announced the launch of the Atellica AIA, an advanced immunoassay analyzer that enhances laboratory efficiency and accuracy. This innovative system streamlines workflows and improves turnaround times for patient results, positioning Siemens as a leader in diagnostic technology. The upgrade is expected to drive growth by attracting more laboratory partnerships and increasing market share
- In March 2024, Siemens Healthineers unveiled its new Fast Track Diagnostic (FTD) service, designed to accelerate diagnostic processes in healthcare facilities. This service enhances efficiency by reducing turnaround times for test results and optimizing laboratory workflows. By improving patient care and operational performance, Siemens aims to strengthen its market position and attract more healthcare providers seeking advanced diagnostic solutions
- In September 2023, Abbott completed its acquisition of Bigfoot Biomedical, enhancing its diabetes care portfolio with advanced insulin management systems. This move strengthens Abbott's FreeStyle Libre continuous glucose monitoring technology and supports its goal of personalized diabetes management. Financial terms were not disclosed
